Related Experiment Video
Updated: Jun 23, 2026
07:09
Assessment of Pulmonary Capillary Blood Volume, Membrane Diffusing Capacity, and Intrapulmonary Arteriovenous Anastomoses During Exercise
Published on: February 20, 2017
Inhaled bronchodilators increase maximum oxygen consumption in chronic left ventricular failure
N G Uren1, S W Davies, S L Jordan
1Department of Cardiology, Royal Free Hospital, London, U.K.
European Heart Journal
|June 1, 1993
Summary
Bronchodilator agents like salbutamol and ipratropium bromide improve exercise capacity in chronic heart failure patients by reducing bronchoconstriction. This suggests airway narrowing contributes to exercise limitation in heart failure.
Area of Science:
- Cardiology
- Pulmonology
- Exercise Physiology
Background:
- Bronchoconstriction is observed in patients with chronic heart failure (CHF).
- This airway narrowing may limit exercise capacity in individuals with CHF.
Purpose of the Study:
- To investigate the impact of bronchodilator agents on exercise capacity in CHF patients.
- To determine if bronchodilators can alleviate exercise limitation caused by bronchoconstriction in CHF.
Main Methods:
- A randomized, double-blind, placebo-controlled study was conducted.
- 10 patients with NYHA class II/III CHF underwent maximal exercise testing.
- Patients received nebulized salbutamol, ipratropium bromide, or placebo on separate days.
Main Results:
- Salbutamol and ipratropium bromide significantly increased forced expiratory volume in one second (FEV1).
- Maximal oxygen consumption (VO2 max) and peak minute ventilation during exercise increased significantly after bronchodilator use compared to placebo.
- These improvements indicate enhanced exercise capacity following bronchodilator administration.
Conclusions:
- Bronchodilator agents provide a small but significant improvement in exercise capacity for patients with CHF.
- The findings imply that bronchoconstriction is present in CHF and contributes to exercise limitation.
- Targeting bronchoconstriction may be a viable strategy to improve functional capacity in heart failure management.
Related Concept Videos
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:24Chronic Obstructive Pulmonary Disease
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
01:29Chronic Obstructive Pulmonary Disease-V: Management
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
01:24Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...